Gravitate Health FHIR Implementation Guide
0.1.0 - CI Build
Gravitate Health FHIR Implementation Guide
0.1.0 - CI Build
Gravitate Health FHIR Implementation Guide, published by Gravitate Health Project. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/joofio/test-epi-composition/ and changes regularly. See the Directory of published versions
<Bundle xmlns="http://hl7.org/fhir">
<id value="bundlepackageleaflet-en-7fd8db306f75e7eea8a1de8f7d7fbab2"/>
<meta>
<profile
value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Bundle-uv-epi"/>
</meta>
<language value="en"/>
<identifier>
<system value="http://ema.europa.eu/identifier"/>
<value value="None"/>
</identifier>
<type value="document"/>
<timestamp value="2023-06-27T10:09:22Z"/>
<entry>
<fullUrl
value="Composition/composition-en-7fd8db306f75e7eea8a1de8f7d7fbab2"/>
<resource>
<Composition>
<id value="composition-en-7fd8db306f75e7eea8a1de8f7d7fbab2"/>
<meta>
<profile
value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Composition-uv-epi"/>
</meta>
<language value="en"/>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en"><a name="Composition_composition-en-7fd8db306f75e7eea8a1de8f7d7fbab2"> </a><p class="res-header-id"><b>Generated Narrative: Composition composition-en-7fd8db306f75e7eea8a1de8f7d7fbab2</b></p><a name="composition-en-7fd8db306f75e7eea8a1de8f7d7fbab2"> </a><a name="hccomposition-en-7fd8db306f75e7eea8a1de8f7d7fbab2"> </a><a name="composition-en-7fd8db306f75e7eea8a1de8f7d7fbab2-en-US"> </a><div style="display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%"><p style="margin-bottom: 0px">Language: en</p><p style="margin-bottom: 0px">Profile: <a href="https://build.fhir.org/ig/HL7/emedicinal-product-info/StructureDefinition-Composition-uv-epi.html">Composition (ePI)</a></p></div><p><b>identifier</b>: <code>http://ema.europa.eu/identifier</code>/EU/1/18/1331/001</p><p><b>status</b>: Final</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/rmswi/ 100000155538}">Package Leaflet</span></p><p><b>category</b>: <span title="Codes:{http://hl7.eu/fhir/ig/gravitate-health/CodeSystem/epicategory-cs R}">Raw</span></p><p><b>date</b>: 2022-02-16 13:28:17+0000</p><p><b>author</b>: <a href="Organization-mah-ema.html">Organization ACME industry</a></p><p><b>title</b>: TEST PURPOSES ONLY - luxturna</p><h3>Attesters</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Mode</b></td><td><b>Time</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{http://hl7.org/fhir/composition-attestation-mode official}">Official</span></td><td>2022-02-16 13:28:17+0000</td></tr></table></div>
</text>
<identifier>
<system value="http://ema.europa.eu/identifier"/>
<value value="EU/1/18/1331/001"/>
</identifier>
<status value="final"/>
<type>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="Package Leaflet"/>
</type>
<category>
<coding>
<system
value="http://hl7.eu/fhir/ig/gravitate-health/CodeSystem/epicategory-cs"/>
<code value="R"/>
<display value="Raw"/>
</coding>
</category>
<subject>
<reference
value="MedicinalProductDefinition/mp7fd8db306f75e7eea8a1de8f7d7fbab2"/>
</subject>
<date value="2022-02-16T13:28:17Z"/>
<author>🔗
<reference value="Organization/mah-ema"/>
</author>
<title value="TEST PURPOSES ONLY - luxturna"/>
<attester>
<mode>
<coding>
<system
value="http://hl7.org/fhir/composition-attestation-mode"/>
<code value="official"/>
</coding>
</mode>
<time value="2022-02-16T13:28:17Z"/>
</attester>
<section>
<title value="B. Package Leaflet"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="B. Package Leaflet"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml">unavailable</div>
</text>
<emptyReason>
<coding>
<system
value="http://terminology.hl7.org/CodeSystem/list-empty-reason"/>
<code value="unavailable"/>
</coding>
</emptyReason>
<section>
<title value="Package leaflet: Information for the user"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="Package leaflet: Information for the user"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"></div>
</text>
</section>
<section>
<title value="What is in this leaflet"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="What is in this leaflet"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>What is in this leaflet:</p><ol type="1"><li>What Luxturna is and what it is used for</li><li>What you need to know before you are given Luxturna</li><li>How Luxturna is given to you</li><li>Possible side effects</li><li>How Luxturna is stored</li><li>Contents of the pack and other information</li></ol></div>
</text>
</section>
<section>
<title value="1. What luxturna is and what it is used for"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="1. What luxturna is and what it is used for"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Luxturna is a gene therapy product that contains the active substance voretigene neparvovec.</p><p>Luxturna is used for the treatment of adults and children with vision loss due to inherited retinal dystrophy caused by mutations in the RPE65 gene. These mutations prevent the body from producing a protein needed for vision and so lead to loss of sight and eventual blindness.</p><p>The active substance in Luxturna, voretigene neparvovec, is a modified virus that contains a working copy of the RPE65 gene. After injection it delivers this gene into the cells of the retina, the layer at the back of the eye that detects light. This enables the retina to produce the proteins needed for vision. The virus used to deliver the gene does not cause disease in humans.</p><p>Luxturna will be given to you only if genetic testing shows that your vision loss is caused by mutations in the RPE65 gene.</p></div>
</text>
</section>
<section>
<title value="2. What you need to know before you take luxturna"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text
value="2. What you need to know before you take luxturna"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>You will not be given Luxturna</p><ul><li>if you are allergic to voretigene neparvovec or any of the other ingredients of this medicine (listed in section 6)</li><li>if you have an eye infection</li><li>if you have eye inflammation</li></ul><p>If any of the above applies to you, or if you are unsure of any of the above, please talk to your doctor before you receive Luxturna.</p><p>Warnings and precautions Before receiving treatment with Luxturna:</p><ul><li>Tell your doctor if you have signs of an eye infection or eye inflammation, for example if you have eye redness, sensitivity to light, eye swelling or eye pain.</li><li>Tell your doctor if you have an active infection of any sort. Your doctor may delay your treatment until your infection is gone because this medicine may make it more difficult for you to fight an infection. See also section 3. After receiving Luxturna:</li><li>Get immediate care from your doctor if your eye or eyes become red, painful, sensitive to light, you see flashes or floaters in your vision, or if you notice any worsening or blurred vision.</li><li>You should avoid air travel or other travel to high elevations until advised by your doctor. During treatment with this medicine, the doctor inserts an air bubble in the eye, which is slowly absorbed by your body. Until the bubble is fully absorbed, air travel or other travel to high elevations may make the bubble expand and lead to eye damage, including vision loss. Please talk to your doctor before travelling.</li><li>You should avoid swimming because of an increased risk of infection in the eye. Please talk to your doctor before going to swim after receiving treatment with Luxturna.</li><li>You should avoid strenuous physical activity because of an increased risk of injury to the eye. Please talk to your doctor before beginning to engage in strenuous physical activity after receiving Luxturna.</li><li>You may have temporary visual disturbances, such as light sensitivity, and blurred vision. Tell your doctor about any visual disturbances that you experience. Your doctor may be able to help reduce any discomfort caused by these temporary disturbances.</li><li>The active substance in Luxturna may temporarily be excreted through your tears. You and your caregiver should place any used dressings and waste material with tears and nasal secretions in sealed bags before disposing of them. You should follow these precautions for 14 days.</li><li>You might not be able to donate blood, organs, tissues and cells for transplantation after you have been treated with Luxturna.</li></ul><p>Children and adolescents Luxturna has not been studied in children below 4 years of age. Data are limited.</p><p>Other medicines and Luxturna Tell your doctor if you are taking, have recently taken or might take any other medicines.</p><p>Pregnancy, breast-feeding and fertility If you are pregnant or breast-feeding, think you might be pregnant, or are planning to have a baby, ask your doctor or nurse for advice before being treated with Luxturna.</p><p>The effects of this medicine on pregnancy and the unborn child are not known. As a precaution, you should not receive Luxturna while you are pregnant.</p><p>Luxturna has not been studied in breast-feeding women. It is not known whether it passes into breast milk. Tell your doctor if you are breast-feeding or plan to do so. Your doctor will then help you decide whether to stop breast-feeding or to not receive Luxturna, taking into account the benefit of breast- feeding for your baby and the benefit of Luxturna for you.</p><p>Driving and using machines You may have temporary visual disturbances after receiving Luxturna. Do not drive or use heavy machines until your vision has recovered. Talk to your doctor before resuming these activities.</p><p>Luxturna contains sodium This medicine contains less than 1 mmol sodium (23 mg) per dose, that is to say essentially sodium-free .</p></div>
</text>
</section>
<section>
<title value="3. How to take luxturna"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="3. How to take luxturna"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Luxturna will be given to you in an operating room by surgeons experienced in performing eye surgery.</p><p>Luxturna is given under anaesthesia. Your doctor will talk to you about the anaesthesia and how it will be given to you.</p><p>Your doctor will carry out eye surgery to remove the clear gel inside the eye, and then inject Luxturna directly under your retina, the thin light-sensing layer at the back of that eye. This will be repeated on your other eye at least 6 days afterwards. You will need to stay for post-operative observation for a few hours after each procedure to monitor your recovery and watch for any side effects from the surgery or the anaesthesia.</p><p>Before Luxturna treatment is started your doctor may ask you to take a medicine that will suppress your immune system (the body s natural defences) so that it will not try to fight the Luxturna when it is given. It is important that you take this medicine according to the instructions given. Do not stop taking the medicine without first talking to your doctor.</p><p>If you are given more Luxturna than you should be As this medicine is given to you by a doctor, it is unlikely that you will be given too much. If it does occur, your doctor will treat the symptoms as necessary. Tell your doctor or nurse if you have any visual problems.</p><p>If you have any further questions on the use of this medicine, ask your doctor or nurse.</p></div>
</text>
</section>
<section>
<title value="4. Possible side effects"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="4. Possible side effects"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>The following side effects may happen with Luxturna:</p><p>Common (may affect up to 1 in 10 people)</p><ul><li>Deposits under the retina</li></ul><p>The following side effects may happen with the injection procedure:</p><p>Very common (may affect more than 1 in 10 people)</p><ul><li>Redness of the eye</li><li>Cataract (clouding of the lens)</li><li>Increased pressure in the eye</li></ul><p>Common (may affect up to 1 in 10 people)</p><ul><li>Break in the retina</li><li>Eye pain</li><li>Eye swelling</li><li>Detachment of the retina</li><li>Bleeding in the back of the eye</li><li>Pain or increased discomfort in the eye</li><li>Blurring of central vision due to hole in the centre of the retina</li><li>Thinning of the surface of the eye (dellen)</li><li>Eye irritation</li><li>Eye inflammation</li><li>Foreign body sensation in the eye</li><li>Eye discomfort</li><li>Abnormalities in the back of the eye</li><li>Nausea (feeling sick), vomiting, abdominal (belly) pain, lip pain</li><li>Change of the electrical activity of the heart</li><li>Headache, dizziness</li><li>Rash, facial swelling</li><li>Anxiety</li><li>Problems associated with the placement of a breathing tube in the windpipe</li><li>Breakdown of the surgical wound</li></ul><p>Not known (frequency cannot be estimated from the available data)</p><ul><li>Clouding in the gel-like substance inside the eye (vitreous opacities)</li><li>Atrophy of the (chorio)retina</li></ul><p>Damage to the tissues of the eye may be accompanied by bleeding and swelling and an increased risk of infection. There is reduced vision in the days after surgery that usually improves; tell your doctor if vision does not return.</p><p>Reporting of side effects If you get any side effects, talk to your doctor or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects, you can help provide more information on the safety of this medicine.</p></div>
</text>
</section>
<section>
<title value="5. How to store luxturna"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="5. How to store luxturna"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Luxturna will be stored by the healthcare professionals at your healthcare facility. Concentrate and solvent must be stored and transported frozen at -65 C. Once thawed, the medicine should not be re-frozen and should be left at room temperature (below 25 C). Do not use this medicine after the expiry date which is stated on the label and carton after EXP.</p></div>
</text>
</section>
<section>
<title value="6. Contents of the pack and other information"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="6. Contents of the pack and other information"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>What Luxturna contains</p><ul><li>The active substance is voretigene neparvovec. Each mL of concentrate contains 5 1012 vector genomes (vg). The concentrate (0.5 mL extractable volume in a single-dose 2 mL vial) requires a 1:10 dilution prior to administration.</li><li>Each dose of diluted solution contains 1.5 1011 vector genomes of voretigene neparvovec in a deliverable volume of 0.3 mL.</li><li>The other ingredients of the concentrate are sodium chloride (see Luxturna contains sodium in section 2 of this leaflet), sodium dihydrogen phosphate monohydrate (for pH adjustment), disodium hydrogen phosphate dihydrate (for pH adjustment), poloxamer 188 and water for injections.</li><li>The solvent contains sodium chloride (see end of section 2), sodium dihydrogen phosphate monohydrate (for pH adjustment), disodium hydrogen phosphate dihydrate (for pH adjustment), poloxamer 188 and water for injections.</li></ul><p>This medicine contains genetically modified organisms.</p><p>What Luxturna looks like and contents of the pack Luxturna is a clear, colourless concentrate for solution for subretinal injection, supplied in a clear plastic vial. The solvent is a clear, colourless liquid supplied in a clear plastic vial.</p><p>Each foil pouch includes a carton containing 1 vial of 0.5 mL concentrate and 2 vials of solvent (each containing 1.7 mL).</p><p>Marketing Authorisation Holder Novartis Europharm Limited Vista Building Elm Park, Merrion Road Dublin 4 Ireland</p><p>Manufacturer Novartis Pharma GmbH Roonstrasse 90429 Nuremberg Germany</p><p>For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:</p><p>Belgi /Belgique/Belgien Novartis Pharma N.V. T l/Tel: +32 2 246 16 Lietuva SIA Novartis Baltics Lietuvos filialas Tel: +370 5 269 16<br/>Novartis Bulgaria EOOD : +359 2 489 98 Luxembourg/Luxemburg Novartis Pharma N.V. T l/Tel: +32 2 246 16 esk republika Novartis s.r.o. Tel: +420 225 775 Magyarorsz g Novartis Hung ria Kft. Tel.: +36 1 457 65 Danmark Novartis Healthcare A/S Tlf: +45 39 16 84 Malta Novartis Pharma Services Inc. Tel: +356 2122 2Deutschland Novartis Pharma GmbH Tel: +49 911 273 0</p><p>Nederland Novartis Pharma B.V. Tel: +31 88 04 52 Eesti SIA Novartis Baltics Eesti filiaal Tel: +372 66 30 Norge Novartis Norge AS Tlf: +47 23 05 20<br/>Novartis (Hellas) A.E.B.E. : +30 210 281 17 sterreich Novartis Pharma GmbH Tel: +43 1 86 6Espa a Novartis Farmac utica, S.A. Tel: +34 93 306 42 Polska Novartis Poland Sp. z o.o. Tel.: +48 22 375 4France Novartis Pharma S.A.S. T l: +33 1 55 47 66 Portugal Novartis Farma - Produtos Farmac uticos, S.A. Tel: +351 21 000 8Hrvatska Novartis Hrvatska d.o.o. Tel. +385 1 6274 Rom nia Novartis Pharma Services Romania SRL Tel: +40 21 31299 Ireland Novartis Ireland Limited Tel: +353 1 260 12 Slovenija Novartis Pharma Services Inc. Tel: +386 1 300 75 sland Vistor hf. S mi: +354 535 7Slovensk republika Novartis Slovakia s.r.o. Tel: +421 2 5542 5Italia Novartis Farma S.p.A. Tel: +39 02 96 54 1 Suomi/Finland Novartis Finland Oy Puh/Tel: +358 (0)10 6133<br/>Novartis Pharma Services Inc. : +357 22 690 Sverige Novartis Sverige AB Tel: +46 8 732 32 Latvija SIA Novartis Baltics Tel: +371 67 887 United Kingdom (Northern Ireland) Novartis Ireland Limited Tel: +44 1276 698This leaflet was last revised in</p><p>Other sources of information This leaflet is available as an audio file and in a large print from the web site: <a href="http://www.voretigeneneparvovec.support">http://www.voretigeneneparvovec.support</a></p><p>Detailed information on this medicine is available on the European Medicines Agency web site:</p></div>
</text>
</section>
</section>
</Composition>
</resource>
</entry>
<entry>
<fullUrl
value="MedicinalProductDefinition/mp7fd8db306f75e7eea8a1de8f7d7fbab2"/>
<resource>
<MedicinalProductDefinition>
<id value="mp7fd8db306f75e7eea8a1de8f7d7fbab2"/>
<meta>
<profile
value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/MedicinalProductDefinition-uv-epi"/>
</meta>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml"><a name="MedicinalProductDefinition_mp7fd8db306f75e7eea8a1de8f7d7fbab2"> </a><p class="res-header-id"><b>Generated Narrative: MedicinalProductDefinition mp7fd8db306f75e7eea8a1de8f7d7fbab2</b></p><a name="mp7fd8db306f75e7eea8a1de8f7d7fbab2"> </a><a name="hcmp7fd8db306f75e7eea8a1de8f7d7fbab2"> </a><a name="mp7fd8db306f75e7eea8a1de8f7d7fbab2-en-US"> </a><p><b>identifier</b>: <code>http://ema.europa.eu/identifier</code>/EU/1/18/1331/001</p><p><b>type</b>: <span title="Codes:{http://hl7.org/fhir/medicinal-product-type MedicinalProduct}">Medicinal Product</span></p><p><b>domain</b>: <span title="Codes:{http://hl7.org/fhir/medicinal-product-domain Human}">Human use</span></p><p><b>status</b>: <span title="Codes:{http://hl7.org/fhir/publication-status active}">active</span></p><p><b>legalStatusOfSupply</b>: <span title="Codes:{https://spor.ema.europa.eu/rmswi 100000072084}">Medicinal product subject to medical prescription</span></p><blockquote><p><b>name</b></p><p><b>productName</b>: Luxturna 5 × 1012 vector genomes/mL concentrate and solvent for solution for injection</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000001}">Full name</span></p><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000002}">Invented name part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000003}">Scientific name part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000004}">Strength part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000005}">Pharmaceutical dose form part</span></p></blockquote><h3>Usages</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Country</b></td><td><b>Jurisdiction</b></td><td><b>Language</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{urn:iso:std:iso:3166 EU}">EU</span></td><td><span title="Codes:{urn:iso:std:iso:3166 EU}">EU</span></td><td><span title="Codes:{urn:ietf:bcp:47 en}">en</span></td></tr></table></blockquote></div>
</text>
<identifier>
<system value="http://ema.europa.eu/identifier"/>
<value value="EU/1/18/1331/001"/>
</identifier>
<type>
<coding>
<system value="http://hl7.org/fhir/medicinal-product-type"/>
<code value="MedicinalProduct"/>
<display value="Medicinal Product"/>
</coding>
</type>
<domain>
<coding>
<system value="http://hl7.org/fhir/medicinal-product-domain"/>
<code value="Human"/>
<display value="Human use"/>
</coding>
</domain>
<status>
<coding>
<system value="http://hl7.org/fhir/publication-status"/>
<code value="active"/>
<display value="active"/>
</coding>
</status>
<legalStatusOfSupply>
<coding>
<system value="https://spor.ema.europa.eu/rmswi"/>
<code value="100000072084"/>
<display
value="Medicinal product subject to medical prescription"/>
</coding>
</legalStatusOfSupply>
<name>
<productName
value="Luxturna 5 × 1012 vector genomes/mL concentrate and solvent for solution for injection"/>
<type>
<coding>
<system value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000001"/>
<display value="Full name"/>
</coding>
</type>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000002"/>
<display value="Invented name part"/>
</coding>
</type>
</part>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000003"/>
<display value="Scientific name part"/>
</coding>
</type>
</part>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000004"/>
<display value="Strength part"/>
</coding>
</type>
</part>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000005"/>
<display value="Pharmaceutical dose form part"/>
</coding>
</type>
</part>
<usage>
<country>
<coding>
<system value="urn:iso:std:iso:3166"/>
<code value="EU"/>
<display value="EU"/>
</coding>
</country>
<jurisdiction>
<coding>
<system value="urn:iso:std:iso:3166"/>
<code value="EU"/>
<display value="EU"/>
</coding>
</jurisdiction>
<language>
<coding>
<system value="urn:ietf:bcp:47"/>
<code value="en"/>
<display value="en"/>
</coding>
</language>
</usage>
</name>
</MedicinalProductDefinition>
</resource>
</entry>
</Bundle>
IG © 2021+ Gravitate Health Project. Package hl7.eu.fhir.ghepi#0.1.0 based on FHIR 5.0.0. Generated 2024-10-14
Links: Table of Contents |
QA Report
The Gravitate Health project has received funding from the IMI 2 Joint Undertaking under grant agreement No 945334.
This joint undertaking receives support from the EU H2020 research and innovation programme and EFPIA.
